Non-interventional study of treatment approaches in patients with locally advanced prostate cancer who have undergone prostatectomy or radiation therapy (PREVENT)
{"title":"Non-interventional study of treatment approaches in patients with locally advanced prostate cancer who have undergone prostatectomy or radiation therapy (PREVENT)","authors":"V. Matveev, E. I. Kopyl’tsov, P. Borisov","doi":"10.17650/1726-9776-2020-16-3-109-116","DOIUrl":null,"url":null,"abstract":"Background. Prostate cancer (PCa) is the second most common cancer in men. Currently there is no clear understanding of preferences among oncologists in Russia in decision-making process regarding adjuvant ADT in patients with locally advanced PCa with high and very high risk of recurrence after prostatectomy or radiotherapy.Objective: to provide accurate and reliable information regarding the adjuvant endocrine treatment in patients with locally advanced PCa in the Russian routine clinical practice.Materials and methods. This multicentre, non-interventional, prospective observational cohort study included 204 males (mean age 64.9 ± 6.2 years) with locally advanced PCa. The patients were enrolled at 18 sites in Russian Federation. Information on the routine diagnosis-specific examinations, including PSA measurements before, after and during one year after prostatectomy / radiotherapy was collected. Information regarding patient demographics, disease characteristics, management approaches, diagnostic tests and medications received by patients was taken from the medical records.Results. Among patients participated in the study, 64.4 % were treated surgically, and 38.6 % underwent radiotherapy; only 6 patients (4.6 %) underwent radical prostatectomy followed by radiotherapy. Median duration from diagnosis of PCa at the time of enrolment was less than 2.7 months, for 75 % of patients the disease duration did not exceed 7 months. ADT was used in 132 patients. ADT was received by 95.8 % of males treated with radiotherapy without radical prostatectomy and by 46.8 % of those who underwent radical prostatectomy without radiotherapy. Medical or surgical castration was used in 56.4 % of cases, antiandrogens without castration were used by less than 10 % of patients, while 28.2 % of patients received treatment with both castration and antiandrogens and the same number of males underwent only castration. Percentage of patients with PCa progression was 9.3 % for males after radical prostatectomy without radiotherapy and 7.4 % for those who underwent radiotherapy without radical prostatectomy. There were no cases of death due to PCa progression.Conclusion. The results are in alignment with international guidelines and standards. Received data can help to improve management approaches for treatment of Russian patients with high risk locally advanced PCa, particularly giving a basis for a decision on use of ADT.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2020-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkourologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2020-16-3-109-116","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background. Prostate cancer (PCa) is the second most common cancer in men. Currently there is no clear understanding of preferences among oncologists in Russia in decision-making process regarding adjuvant ADT in patients with locally advanced PCa with high and very high risk of recurrence after prostatectomy or radiotherapy.Objective: to provide accurate and reliable information regarding the adjuvant endocrine treatment in patients with locally advanced PCa in the Russian routine clinical practice.Materials and methods. This multicentre, non-interventional, prospective observational cohort study included 204 males (mean age 64.9 ± 6.2 years) with locally advanced PCa. The patients were enrolled at 18 sites in Russian Federation. Information on the routine diagnosis-specific examinations, including PSA measurements before, after and during one year after prostatectomy / radiotherapy was collected. Information regarding patient demographics, disease characteristics, management approaches, diagnostic tests and medications received by patients was taken from the medical records.Results. Among patients participated in the study, 64.4 % were treated surgically, and 38.6 % underwent radiotherapy; only 6 patients (4.6 %) underwent radical prostatectomy followed by radiotherapy. Median duration from diagnosis of PCa at the time of enrolment was less than 2.7 months, for 75 % of patients the disease duration did not exceed 7 months. ADT was used in 132 patients. ADT was received by 95.8 % of males treated with radiotherapy without radical prostatectomy and by 46.8 % of those who underwent radical prostatectomy without radiotherapy. Medical or surgical castration was used in 56.4 % of cases, antiandrogens without castration were used by less than 10 % of patients, while 28.2 % of patients received treatment with both castration and antiandrogens and the same number of males underwent only castration. Percentage of patients with PCa progression was 9.3 % for males after radical prostatectomy without radiotherapy and 7.4 % for those who underwent radiotherapy without radical prostatectomy. There were no cases of death due to PCa progression.Conclusion. The results are in alignment with international guidelines and standards. Received data can help to improve management approaches for treatment of Russian patients with high risk locally advanced PCa, particularly giving a basis for a decision on use of ADT.
期刊介绍:
The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.